Nilafustin (Anidulafungin)

Anidulafungin, the active ingredient in Nilafustin, is an echinocandin antifungal presented as an intravenous solution for intravenous administration. It is used to treat invasive candidiasis, candidemia, esophageal candidiasis and other serious Candida infections in adult patients.

GNH USA supplies Nilafustin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product conforms to European Union regulatory requirements and is manufactured under GMP conditions. Our distribution network ensures timely delivery and temperature‑controlled handling where required.

Anidulafungin is an echinocandin antifungal indicated for serious Candida infections.

- Invasive candidiasis: treatment of bloodstream and deep‑tissue infection caused by susceptible Candida species. - Candidemia: eradication of Candida organisms present in the blood stream. - Esophageal candidiasis: resolution of fungal infection of the esophageal mucosa. - Other serious Candida infections: management of infections such as peritonitis or intra‑abdominal candidiasis caused by susceptible strains.

Adverse reactions may occur with any antifungal therapy.

Common Side Effects: - Fever or chills during infusion. - Elevated liver enzymes. - Nausea or vomiting. - Headache. - Phlebitis at the infusion site.

Serious or Rare Side Effects: - Severe hypersensitivity reactions, including anaphylaxis. - Hepatotoxicity with marked transaminase elevation. - Acute renal failure. - Cardiac arrhythmias. - Severe neutropenia or thrombocytopenia.

Nilafustin should be used with careful clinical monitoring.

- Renal impairment: adjust therapy based on renal function and monitor creatinine. - Hepatic dysfunction: assess liver enzymes before and during treatment. - Pregnancy: safety not established; weigh potential benefits against risks. - Lactation: unknown excretion in breast milk; consider alternative therapy. - Concomitant nephrotoxic drugs: monitor for additive renal toxicity. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Drug interactions may affect efficacy or safety.

Major Interactions (Avoid): - Cyclosporine: increased anidulafungin exposure may raise toxicity risk. - Rifampin: may reduce anidulafungin plasma levels, compromising effectiveness.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): potential additive hepatotoxicity. - Immunosuppressants (e.g., tacrolimus): monitor drug levels for possible changes. - Concomitant nephrotoxic agents: observe renal function closely.